Join PCNA on September 18, 2025, for a virtual educational summit, where cardiovascular nursing meets cutting-edge science and innovation. We’ll explore critical topics shaping patient care, including ATTR-CM, hypertension guideline updates, LDL-C, and Lp(a) management. We’ll also examine how artificial intelligence is transforming nursing practice and decision-making.
This summit is designed to equip you with the latest evidence-based knowledge to elevate your clinical impact and improve cardiovascular outcomes. Earn 2.25 CE contact hours.
Agenda
Time | Session |
---|---|
9:00 AM CT | Opening Remarks |
9:15 AM CT | Hypertension Reimagined: Applying the latest guidelines |
10:00 AM CT | The Role of Artificial Intelligence in Cardiovascular Care: Case Study |
10:45 AM CT | Break |
11:00 AM CT | Unmasking Aortic Stenosis: Sex-Specific Insights for Better Outcomes hosted by Medtronic |
11:45 AM CT | Breaking the Chain: Targeting LDL-C to Stop Atherosclerosis in Its Tracks |
12:30 PM CT | Transforming Heart Failure Management Through Data-Driven Workflows hosted by Abbott Laboratories |
1:15 PM CT | Closing Remarks |
Learning Objectives
Hypertension Reimagined: Applying the latest guidelines
- Discuss the key updates in the newly released hypertension guidelines and their clinical implications.
- Apply evidence-based strategies from the new guidelines to assess, monitor, and manage patients with hypertension across diverse cardiovascular care settings.
- Integrate lifestyle, pharmacologic, procedural – including renal denervation – and team-based approaches into individualized care plans to optimize blood pressure control and improve cardiovascular outcomes.
The Role of Artificial Intelligence in Cardiovascular Care: Case Study
- Discuss the supportive role of AI-driven tools in cardiovascular disease risk assessment, testing, diagnosis and monitoring
- Review considerations such as data privacy, bias in AI algorithms and strategies for integrating patient-centered approaches with AI-assisted care approaches
- Examine a case study of AI-augmentation in transthyretin amyloid cardiomyopathy (ATTR-CM) detection and diagnosis highlighting the partnership of clinician expertise with AI-driven technology
Breaking the Chain: Targeting LDL-C to Stop Atherosclerosis in Its Tracks
-
Identify and stratify patients at high risk for ASCVD, including those with familial hypercholesterolemia, elevated Lp(a) and other high-need populations, using evidence-based risk assessment tools and clinical indicators.
-
Apply current cholesterol management guidelines to improve LDL-C monitoring and optimize lipid-lowering therapy, overcoming barriers such as clinical inertia and treatment nonadherence.
-
Explore the role of the cardiovascular nurse to engage patients in shared decision-making to support long-term LDL-C control and improve access to appropriate therapies.
Thank you to Abbott Laboratories, BridgeBio Pharma, Inc., Medtronic, Merck & Co., Inc., and Novartis Pharmaceuticals for their support of this program.
Accreditation

PhD, RN, ANP-BC, FAAN, FAANP, FACC, FAHA, FPCNA

DNP, CNP, NP

BSN, RN